ADA-SCID market seen reaching $8.11 billion by 2030

The Business Research Company says the adenosine deaminase-severe combined immunodeficiency market will rise from $6.33 billion in 2026 to $8.11 billion by 2030. Growth is expected to be driven by more gene therapy, enzyme replacement and stem cell treatment options, plus rising pediatric diagnoses and rare-disease funding.

Why it matters: - ADA-SCID is a rare inherited immune disorder with life-threatening consequences if diagnosis and treatment are delayed. - Market growth signals expanding demand for specialized diagnostics, supportive care and advanced therapies for rare genetic diseases. - The report also points to broader momentum in rare-disease treatment infrastructure, including more specialized centers and pediatric programs.

What happened: - The Business Research Company released its Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the ADA-SCID market will grow from $5.94 billion in 2025 to $6.33 billion in 2026. - The report projects the market will reach $8.11 billion by 2030. - The report is based in London and dated Oct. 29, 2026. - The company also published a free sample of the market report and the full report.

The details: - The report says 2025 to 2026 growth reflects a 6.6% CAGR. - The report forecasts a 6.4% CAGR from 2026 to 2030. - The report cites limited public awareness, few gene therapy options, heavy dependence on supportive care, limited specialized treatment centers and delays in diagnosis and treatment as current market restraints. - The report says future growth will be supported by autologous stem cell therapies, broader access to enzyme replacement therapies, more specialized hospitals and clinics, more pediatric diagnoses and higher healthcare funding for rare genetic disorders. - The report identifies wider adoption of enzyme replacement therapy, more gene therapy development, more stem cell transplants, growth in pediatric treatment programs and stronger supportive care monitoring as key trends. - ADA-SCID results from a deficiency of the enzyme adenosine deaminase. - The deficiency causes toxic metabolites to build up and interfere with immune-cell development. - Early diagnosis and management are critical to preventing severe infections and complications. - The report says increasing prevalence of genetic disorders is a major growth driver for the market. - The report links that rise to better diagnostics, greater awareness, older parental age, environmental factors and population growth. - As an example, the UK-based Cystic Fibrosis Trust reported that people living with cystic fibrosis rose from 11,148 in 2022 to 11,318 in 2023. - The report says North America held the largest ADA-SCID market share in 2025. - The report attributes North America's lead to advanced healthcare infrastructure, specialized treatment centers and high investment in rare-disease research. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The growth forecast suggests ADA-SCID is moving from a niche treatment category toward a more structured rare-disease market. - The biggest upside appears tied to treatment innovation, while the biggest limitation remains delayed diagnosis and constrained access to specialty care. - North America's market lead suggests the region is already best positioned to convert rare-disease research into commercial adoption.

What's next: - The market will likely track progress in gene therapy, enzyme replacement therapy and stem cell treatment adoption through 2030. - Expanded pediatric screening and more specialized clinics could further support uptake if diagnosis rates improve. - Investors and providers will likely watch whether rare-disease funding closes the access gap between advanced markets and regions with less specialized care.

The bottom line: - ADA-SCID remains a small but growing rare-disease market, with therapy innovation and earlier diagnosis set to shape the next phase of expansion.